Novartis has signed deals with two major health plans, Cigna and Aetna, to reimburse for its new heart failure drug Entresto, Reuters reported. The deals are among the first publicly announced examples of outcomes-based drug pricing. While Novartis discussed using digital health devices as part of its planned Entresto rollout last year, reports about the new payer deals have not mentioned the...
